Search | Clinical Trials Finder

Conditions: Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions: Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres; Other · Biological · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoldering Multiple Myeloma
Interventions: Nivolumab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions: Relatlimab, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 30 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more

Conditions: Malignant Glioma
Interventions: Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Yttrium Y 90 Glass Microspheres; Biological · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bladder Cancer, Melanoma
Interventions: Nivolumab, Nivolumab plus Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Farmington, Connecticut • Middletown, New Jersey • Harrison, New York + 2 more

Conditions: Muscle-invasive Urothelial Carcinoma
Interventions: Autogene Cevumeran, Nivolumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Metastatic Melanoma, Advanced Melanoma
Interventions: Nivolumab, Relatlimab, Ipilimumab, Signatera genome MRD assay; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IVB Prostate Cancer AJCC v8
Interventions: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab; Drug · Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Nivolumab, Ipilimumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Interventions: zanzalintinib, AB521, Nivolumab; Drug · Biological
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Miami, Florida • Orlando, Florida + 11 more

Conditions: Various Advanced Cancer
Interventions: Nivolumab, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 709 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 33
States / cities: Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more

Conditions: Glioblastoma
Interventions: Nivolumab, BMS-986016; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • Bethesda, Maryland

Conditions: Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 26
States / cities: Tucson, Arizona • Sacramento, California • Littleton, Colorado + 19 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000; Drug · Radiation · Device
Lead sponsor: Parker Institute for Cancer Immunotherapy; Other
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 2 more

Conditions: Carcinoma, Hepatocellular
Interventions: CC-122, Nivolumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • New York, New York + 1 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Extra Renal Origin, Clear Cell Adenocarcinoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Providence, Rhode Island

Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms
Interventions: Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia

Conditions: Tumor, Solid
Interventions: agenT-797, Approved ICIs; Drug
Lead sponsor: MiNK Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 5 more

Conditions: Melanoma, Renal Cell Carcinoma, Metastatic
Interventions: IL-2 and Nivolumab; Drug
Lead sponsor: Gregory Daniels; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Non Small Cell Lung Cancer
Interventions: Nivolumab, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 57
States / cities: Glendale, Arizona • Los Angeles, California • Denver, Colorado + 48 more

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions: Bempegaldesleukin, Nivolumab; Biological
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 62
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Melanoma
Interventions: IO102/IO103, Nivolumab-Relatlimab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions: DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

High Dose IL-2 in Combination With Anti-PD-1

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)